Literature DB >> 28946212

Methyl jasmonate reduces testosterone-induced benign prostatic hyperplasia through regulation of inflammatory and apoptotic processes in rats.

Oluwatosin Adekunle Adaramoye1, Olubukola Oyebimpe Akanni2, Olusoji John Abiola3, Solomon Eduviere Owumi4, Oluyemi Akinloye5, Emiola Olubunmi Olapade-Olaopa6.   

Abstract

BACKGROUND: Phytotherapy is becoming a treatment option in management of diseases including benign prostatic hyperplasia (BPH). We have shown previously that methyl jasmonate (MeJA) ameliorated BPH, however the underlying mechanism of action remains unknown. This study was designed to investigate in mechanistic terms the protective role of MeJA in BPH.
METHODS: BPH was induced by daily injections of testosterone propionate (TP) (3mg/kg) for 28 days.
RESULTS: The weight and organo-somatic weight of prostate in BPH rats were 6.8 and 5.1 times higher than castrated-control group, respectively. Inflammatory markers; prostatic myeloperoxidase and total nitric oxide were significantly increased in BPH group. The activity of aniline hydroxylase (Phase I drug metabolizing enzyme) was significantly increased in BPH rats by 22%. In BPH group, immuno-histochemistry revealed strong expression of prostatic inducible nitric oxide synthase, cyclooxygenase-2 and Bcl2, while mild expression of p53 and Bax were seen. Serum triglyceride and total cholesterol were significantly increased, while HDL-c was decreased in BPH. Interestingly, MeJA and finasteride (singly or combination) attenuated inflammatory indices and induced apoptotic parameters in BPH rats.
CONCLUSION: MeJA protects against TP-induced BPH via mechanisms that involve anti-inflammation, induction of apoptosis and inhibition of phase I drug metabolizing enzyme.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Apoptosis; Benign prostatic hyperplasia; Inflammation; Methyl jasmonate

Mesh:

Substances:

Year:  2017        PMID: 28946212     DOI: 10.1016/j.biopha.2017.08.106

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib.

Authors:  Feng Li; Laura E Pascal; Jianhua Zhou; Yibin Zhou; Ke Wang; Anil V Parwani; Rajiv Dhir; Peng Guo; Dalin He; Joel B Nelson; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2018-02-05

Review 2.  Relationship between Dietary Patterns with Benign Prostatic Hyperplasia and Erectile Dysfunction: A Collaborative Review.

Authors:  Giorgio Ivan Russo; Giuseppe Broggi; Andrea Cocci; Paolo Capogrosso; Marco Falcone; Ioannis Sokolakis; Murat Gül; Rosario Caltabiano; Marina Di Mauro
Journal:  Nutrients       Date:  2021-11-19       Impact factor: 5.717

3.  Mangosteen pericarp components alleviate progression of prostatic hyperplasia and mitochondrial dysfunction in rats.

Authors:  Hui-Hsuan Tsai; Chia-Wen Chen; Pei-Ling Yu; Yu-Ling Lin; Rong-Hong Hsieh
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.